n.a. (ONXX)

pos +0.00
Today's Range: 0.00 - 0.00 | ONXX Avg Daily Volume: 0
Last Update: 12/31/69 - 7:00 PM EST
Volume: 0
YTD Performance: 0.00%
Open: $0.00
Previous Close: $0.00
52 Week Range: $0.00 - $0.00
Oustanding Shares: 0
Market Cap: 0
6-Month Chart
TheStreet Ratings Grade for ONXX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy
Moderate Buy
Moderate Sell
Strong Sell
Mean Rec. 0.00 0.00 0.00 0.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
ONXX Sector Avg. S&P 500
0.00 0.00 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
Revenue 0.00 0.00 0.00
Net Income 0.00 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for ONXX:
Revenue 0.00B
Average Earnings Estimates

Earnings Estimates data is not available for ONXX.

Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

Robert Lang

 | Dec 29, 2013 | 11:00 AM EST

Take a long, hard look at yourself -- and at the Fed.


Jim Cramer

 | Aug 26, 2013 | 10:23 AM EDT
Jim Cramer gives his take on trending Twitter topics including Amgen's purchase of Onyx and the fallout from Nasdaq's trading glitch.

Ed Ponsi

 | Aug 26, 2013 | 7:07 AM EDT
It's an honor to fill in for the one and only Doug Kass here on the Diary.

bearishOnyx Pharmaceuticals downgraded at Leerink

Aug 12, 2013 | 8:12 AM EDT

ONXX was downgraded from Outperform to Market Perform, Leerink Swann said. Valuation call, based on a $140 price target.

bearishOnyx Pharmaceuticals downgraded at BMO

Aug 9, 2013 | 8:17 AM EDT

ONXX was downgraded from Outperform to Market Perform, BMO Capital said. $143 price target. Company is seeing slower sales growth. 

bearishOnyx Pharmaceuticals downgraded at Jefferies

Aug 2, 2013 | 8:36 AM EDT

Shares of ONXX were downgraded to Hold because recent acquisition interest makes upside from here more difficult, Jefferies said.

bearishOnyx Pharmaceuticals downgraded at Baird

Jul 29, 2013 | 7:38 AM EDT

ONXX was downgraded from Outperform to Neutral, Robert Baird said. See limited upside potential to Amgen's bid for the company.


bearishOnyx Pharmaceuticals downgraded at Deutsche

Jul 22, 2013 | 8:11 AM EDT

ONXX was downgraded from Buy to Hold, Deutsche Bank said. $140 price target. Company likely to be acquired, but expect limted upside potential from current levels. 


Robert Lang

 | Jul 12, 2013 | 2:23 PM EDT
There have been some really good winners this year.

Jim Cramer

 | Jul 2, 2013 | 6:00 AM EDT

Thanks to handwringing about macro issues, I missed one of the hottest IPOs in recent memory.


News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.